Estrella Immunopharma
ESLA
16 hedge funds and large institutions have $28.7M invested in Estrella Immunopharma in 2021 Q3 according to their latest regulatory filings, with 16 funds opening new positions, increasing their positions, reducing their positions, and closing their positions.
61.23% more ownership
Funds ownership: 0% → 61.23% (+61%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Karpus Investment Management
Pittsford,
New York
|
+$7.66M |
| 2 |
ASM
ATW SPAC Management
New York
|
+$3.84M |
| 3 |
Boothbay Fund Management
New York
|
+$3.84M |
| 4 |
KPF
K2 Principal Fund
Toronto,
Ontario, Canada
|
+$2.83M |
| 5 |
D.E. Shaw & Co
New York
|
+$1.94M |
Top Sellers
ESLA Hedge Fund Activity: Q3 2021 in Review
16 of the 5,731 institutional investors tracked by Wall St. Rank reported a position in Estrella Immunopharma (ESLA) for Q3 2021, worth a combined $28.7M.
Buyers outnumbered sellers: 16 funds opened new ESLA positions and 0 closed out — a net gain of 16 holders — while 0 added to existing stakes and 0 trimmed.
The largest buyer was Karpus Investment Management, opening a new position worth an estimated $7.66M.
- 16 institutional investors held Estrella Immunopharma (ESLA) as of Q3 2021, up from 0 in Q2 2021.
- Funds reported $28.7M of Estrella Immunopharma stock for Q3 2021.
- 16 funds opened new Estrella Immunopharma positions in Q3 2021 and 0 closed out, a net change of +16 holders.
- The largest Estrella Immunopharma buyer in Q3 2021 was Karpus Investment Management, an estimated $7.66M added.
Based on aggregated 13F filings for Q3 2021.